Weekly Digest - August 2025

Weekly Digest - August 2025

04 August 2025: Alphamab Oncology announces IND application for innovative PD-L1/αvβ6 bispecific ADC JSKN022 was officially accepted by CDE

  • Alphamab Oncology’s IND application for JSKN022, a first-in-class PD-L1/αvβ6 bispecific ADC, has been accepted by China’s CDE for advanced malignant solid tumors
  • Preclinical studies showed potent antitumor activity in PD-L1 and αvβ6-positive tumor models. No ADCs against these targets are yet approved worldwide
  • The upcoming Phase 1 trial will assess safety, tolerability, PK/PD, efficacy, and determine MTD/RP2D in patients with advanced solid tumors refractory to standard therapies
  • JSKN022 is developed in-house using Alphamab’s glycan-specific conjugation platform, linking a topoisomerase I inhibitor (T01) via a cleavable linker

For full story click  here

Share this

Facebook
fb-share-icon
Twitter
Tweet
LinkedIn
Share
Home